Document is current

Article History

Received: 19 March 2024

Revised: 11 November 2024

Accepted: 22 November 2024

First Online: 10 January 2025

Competing interests

: DM is a consultant for, and has equity in, BiomeSense, Inc. ME is the chief science officer and has equity at Innovate Phytoceuticals Inc. He is a scientific advisor and holds equity at Melius Microbiomics Inc. BWD has received research support from Beckley PsyTech, Boehringer Ingelheim, Compass Pathways, NIMH, Otsuka, Reunion Neuroscience, and the Usona Institute, and has served as a consultant for Biohaven, Cerebral Therapeutics, Myriad Neuroscience, NRx Pharmaceuticals, and Otsuka. RK-D is an inventor on key patents in the field of Metabolomics and holds equity in Metabolon. In addition, she holds patents licensed to Chymia LLC and PsyProtix with royalties and ownership. PD (of the AGMP consortium) is an advisor and holds equity in Cybele and Sirenas and a Scientific co-founder, advisor and holds equity to Ometa, Enveda, and Arome with prior approval by UC San Diego. PD also consulted for DSM animal health in 2023. RK is a scientific advisory board member, and consultant for BiomeSense, Inc., has equity and receives income. He is a scientific advisory board member and has equity in GenCirq. He is a consultant and scientific advisory board member for DayTwo, and receives income. He has equity in and acts as a consultant for Cybele. He is a co-founder of Biota, Inc., and has equity. He is a cofounder of Micronoma, and has equity and is a scientific advisory board member. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The companies listed here had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the paper; and decision to submit the paper for publication.